Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study

医学 卡铂 培美曲塞 内科学 白细胞清除术 临床终点 腹膜间皮瘤 化疗 间皮瘤 外科 肿瘤科 随机对照试验 顺铂 病理 干细胞 川地34 生物 遗传学
作者
Joachim G.J.V. Aerts,Robert A. Belderbos,Paul Baas,Arnaud Scherpereel,Koen Bezemer,Ilona C. Enninga,Rob R. Meijer,Marcella Willemsen,Rossana Berardi,Dean A. Fennell,René Kerstens,Robin Cornelissen,Jan P. van Meerbeeck
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (7): 865-878 被引量:2
标识
DOI:10.1016/s1470-2045(24)00191-8
摘要

Background Dendritic cell immunotherapy has proven to be safe and induces an immune response in humans. We aimed to establish the efficacy of dendritic cells loaded with allogeneic tumour cell lysate (MesoPher, Amphera BV, 's-Hertogenbosch, Netherlands) as maintenance therapy in patients with pleural mesothelioma. Methods In this open-label, randomised, phase 2/3 study, patients with histologically confirmed unresectable pleural mesothelioma, aged 18 years or older, with an Eastern Cooperative Oncology Group performance status score of 0–1, and non-progressing disease after four to six cycles of standard chemotherapy (with pemetrexed 500 mg/m2 plus platinum [cisplatin 75 mg/m2 or carboplatin area under the curve of 5]) were recruited from four centres in Belgium, France, and The Netherlands. Participants were randomly assigned (1:1), using block randomisation (block size of 4), stratified by centre and histology (epithelioid vs other), to MesoPher treatment plus best supportive care or best supportive care alone. Patients received up to a maximum of five MesoPher infusions, with treatment administered on days 1, 15, and 29, and weeks 18 and 30. At each timepoint, participants received an injection of 25 × 106 dendritic cells (two-thirds of the dendritic cells were administered intravenously and a third were injected intradermally). Best supportive care was per local institutional standards. The primary endpoint was overall survival, assessed in all participants randomly assigned to treatment (full analysis set) and safety assessed in all randomly assigned participants, and who underwent leukapheresis if they were in the MesoPher group. This study is registered with ClinicalTrials.gov, NCT03610360, and is closed for accrual. Findings Between June 21, 2018, and June 10, 2021, 176 patients were screened and randomly assigned to the MesoPher group (n=88) or best supportive care alone group (n=88). One participant in the MesoPher group did not undergo leukapheresis. Mean age was 68 years (SD 8), 149 (85%) of 176 were male, 27 (15%) were female, 173 (98%) were White, two were Asian (1%), and one (1%) was other race. As of data cutoff (June 24, 2023), after a median follow up of 15·1 months (IQR 9·5–22·4), median overall survival was 16·8 months (95% CI 12·4–20·3; 61 [69%] of 88 died) in the MesoPher group and 18·3 months (14·3–21·9; 59 [67%] of 88 died) in the best supportive care group (hazard ratio 1·10 [95% CI 0·77–1·57]; log-rank p=0·62). The most common grade 3–4 treatment-emergent adverse events were chest pain (three [3%] of 87 in the MesoPher group vs two [2%] of 88 in the best supportive care group), dyspnoea (none vs two [2%]), anaemia (two [2%] vs none), nausea (none vs two [2%]), and pneumonia (none vs two [2%]). No deaths due to treatment-emergent adverse events were recorded. Treatment-related adverse events consisted of infusion-related reactions (fever, chills, and fatigue), which occurred in 64 (74%) of 87 patients in the MesoPher group, and injection-site reactions (itch, erythema, and induration), which occurred in 73 (84%) patients, and all were grade 1–2 in severity. No deaths were determined to be treatment related. Interpretation MesoPher did not show improvement in overall survival in patients with pleural mesothelioma. Immune checkpoint therapy is now standard of care in pleural mesothelioma. Further randomised studies are needed of combinations of MesoPher and immune checkpoint therapy, which might increase efficacy without adding major toxicities. Funding Amphera BV and EU HORIZON.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
笨笨以莲发布了新的文献求助20
3秒前
小广完成签到,获得积分10
3秒前
田様应助大橙子采纳,获得10
6秒前
6秒前
SYLH应助Echo_1995采纳,获得10
8秒前
吕小布完成签到,获得积分10
9秒前
骑驴追火箭完成签到,获得积分10
11秒前
baomingqiu完成签到 ,获得积分10
11秒前
乐观寻雪完成签到 ,获得积分10
13秒前
量子星尘发布了新的文献求助10
14秒前
复杂勒完成签到,获得积分10
14秒前
15秒前
bird完成签到,获得积分10
16秒前
AaronDP发布了新的文献求助50
17秒前
terryok完成签到,获得积分10
18秒前
Cll完成签到 ,获得积分10
18秒前
聪明的宛菡完成签到,获得积分10
19秒前
CNYDNZB完成签到 ,获得积分10
19秒前
xxj完成签到 ,获得积分10
19秒前
芊芊完成签到 ,获得积分10
20秒前
yar应助bluesky采纳,获得10
20秒前
海人完成签到 ,获得积分10
21秒前
SY15732023811完成签到 ,获得积分10
23秒前
李建勋完成签到,获得积分10
23秒前
科研通AI2S应助一路芬芳采纳,获得10
23秒前
黄花完成签到 ,获得积分10
24秒前
刘珍荣完成签到,获得积分10
25秒前
25秒前
紫金之巅完成签到 ,获得积分10
25秒前
Gang完成签到,获得积分10
26秒前
27秒前
27秒前
28秒前
CYYDNDB完成签到 ,获得积分10
28秒前
粿粿一定行完成签到 ,获得积分10
29秒前
30秒前
战战完成签到,获得积分10
31秒前
xlk2222完成签到,获得积分10
34秒前
笨笨以莲完成签到,获得积分10
34秒前
YHX完成签到,获得积分10
35秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022